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Follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma with an ability to transform into a more
aggressive disease, albeit infrequently to B-lymphoblastic leukemia/lymphoma. While t(14;18)(q32;q21) has been
associated with approximately 90% cases of FL, that alteration alone is insufficient to cause FL and associated
mutations are still being elucidated. The transformation of FL to B-lymphoblastic leukemia generally includes the
dysregulation of MYC gene expression, typically through IGH rearrangement. Such cases of “double-hit” leukemia/
lymphoma with both BCL2 and MYC translocations warrant further study as they are often not identified early, are
associated with a poor prognosis, and are incompletely understood in molecular terms. Here we describe a patient
with a diagnosis of FL that transformed to B-lymphoblastic leukemia. Detailed cytogenetic characterization of the
transformed specimen using karyotype, fluorescence in situ hybridization, microarray and gene rearrangement
analyses revealed a complex karyotype comprised principally of whole chromosome or whole arm copy number
gains or losses. Smaller, single-gene copy number alterations identified by microarray were limited in number, but
included amplification of a truncated EP300 gene and alterations in NEIL1 and GPHN. Analyses defined the presence
of an IGH/BCL2 fusion due to a translocation as well as a MYC/IGH fusion due to an insertion, with both
rearrangements involving the same IGH allele. The data illustrate the value in characterizing double-hit lymphoma
cases with both traditional and novel technologies in the detailed cytogenetic workup.
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Follicular lymphoma (FL) accounts for approximately 30%
of adult non-Hodgkin lymphoma and is generally indolent
in its clinical course. A subset of FL cases transform into a
more aggressive disease, most often to diffuse large B-cell
lymphoma [1]. Transformation to other entities, such as
B- acute lymphoblastic leukemia (B-ALL), is less common
[1-3]. FL is genetically characterized by the presence of
the t(14;18)(q32;q21) chromosomal translocation in ap-
proximately 90% of cases [4]. However, that alteration
alone is insufficient to cause FL and those additional gen-
omic events specifically leading to disease are still being
elucidated. Similarly, those events that mediate transform-
ation of FL to B-ALL remain under investigation, although
dysregulation of MYC gene expression typically through
rearrangement with the immunoglobulin (IG) locus is a* Correspondence: roger.schultz@perkinelmer.com
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reproduction in any medium, provided the orcommon finding. Such cases of “double-hit” leukemia/
lymphoma, defined by a translocation involving MYC in
combination with another translocation involving BCL2,
warrant further study as they are not readily recognized
until transformation has occurred and are associated with
a poor prognosis [5,6]. Here we describe a patient with an
initial diagnosis of FL that transformed to B-ALL. Detailed
molecular and cytogenetic characterization of the
transformed specimen using karyotype, fluorescence in
situ hybridization (FISH), microarray and gene rearrange-
ment analyses revealed the complex nature of the abnor-
malities present in this disease. These findings included a
karyotype with 84-86 chromosomes, principally of whole-
chromosome/whole-arm abnormalities, both IGH/BCL2
and MYC/IGH fusions involving the same single IGH al-
lele, as well as limited single-gene alterations involving
NEIL1, GPNH, and EP300.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A representative karyotype with GTG banding. 84<3n>, XXY,+X,+Y,+1,+2,+2,+5, +del(6)(q13)x2,+del(7)(q11.2),-8,-9,+11,-12,
add(13)(q31)x2,-15,-17,del(18)(q21.1),+20,+21,+21, +21,+22,+5mar.
Table 1 Karyotype and microarray findings in patient
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A 52-year-old man presented with early satiety, fevers
and myalgias. His past medical history was remarkable
for recent recurrent methicillin- resistant Staphylococcus
aureus (MRSA) cellulitis. On biopsy, an inguinal lymph
node was involved with back-to-back lymphoid follicles
containing cells with vesicular chromatin and prominent
nucleoli. The cells of interest were CD45+, CD20+,
CD10+, BCL2+, BCL6+ and kappa restricted; ki-67
stained 30-40% of the cells. A diagnosis of follicular
lymphoma was made and staging studies revealed stageFigure 2 Microarray and FISH findings of transformed follicular lymph
array-based cooperative genomic hybridization (aCGH) are shown for chrom
ratio is reflective of a triploid (3n) genotype (confirmed by karyotypes and
BAC probes illustrate (D) co-localization of MYC and BCL2 on a marker chro
marker. Probe colors match the indicated probe names.3 disease, with supraclavicular, precarinal, mediastinal,
periaortic, iliac and inguinal adenopathy, and spleno-
megaly. Lactate dehydrogenase (LDH) was modestly
elevated. R-CHOP therapy was initiated with two cy-
cles given 32 days apart. The patient’s symptoms re-
solved and he did not receive additional therapy. PET/
CT imaging done 8 weeks and 6 months after cycle 2
showed resolution of adenopathy, splenomegaly and
hypermetabolic activity.
Six months later the patient re-presented with early
satiety, easy bruising and fatigue. His CBC showed WBComa. Copy losses (blue) and copy gains (pink) for oligonucleotide
osomes (A) 8, (B) 14, and (C) 18. Note that the zero value for Log2
FISH), as aCGH cannot discern autosomal ploidy. FISH using indicated
mosome, and (E) co-localization of these genes with IGH on the same
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and platelet 9,000/ul. LDH was within normal limits. A
PET/CT revealed enlarged hypermetabolic lymph nodes
in the neck and chest. Splenomegaly was again seen. A
bone marrow aspirate and biopsy showed >95% cellu-
larity; 65% of the cells were lymphoblasts with CD10+
CD19+ CD38+ CD58+ CD71+ HLA DR+CD79+ and
dim surface lambda positivity. CD20 and kappa were
negative. Fine needle aspiration of a supraclavicular
lymph node yielded a population of lymphoblasts with
the same immunophenotype as the marrow infiltrating
cells. A diagnosis of B-cell ALL was made. The patientFigure 3 Molecular delineation of complex rearrangement of the marke
Panel 2 and standard aCGH are shown for comparison with results indicative
Constant region (class switch) and the other corresponding to the Joining reg
subsequent confirmatory PCR reactions (red arrows), and the location and dir
originated from MYC and BCL2 indicate that MYC is inserted into the IGH, whi
the indicated primers confirm the insertion of MYC gene into IGH Constant rewas treated with 8 cycles of hyperCVAD/MTX-AraC,
enjoyed a brief remission, but subsequently relapsed.
He refused additional aggressive care and died shortly
after relapse.
Molecular and cytogenetic studies
Cytogenetic analysis of the transformed specimen
showed a complex karyotype with cells containing 84-86
chromosomes. A representative karyotype is shown in
Figure 1. Due to the complexity of the abnormalities it
was not possible to discern the presence of any specific
translocation by karyotype. Initial FISH analysis,r chromosome bearing MYC, IGH and BCL2. (A) OncoChip™ | B-ALL
of two rearrangements (black arrows on top), one corresponding to the
ion of the IGH locus as indicated. Locations of primers designed for
ectionality of the MYC and BCL2 genes are also indicated. The lines
le IGH/BCL2 fusion is resulted from a translocation. (B) PCR reactions using
gion and translocation of BCL2 gene to the IGH Joining site.
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atypical IGH/BCL2 fusion signal pattern in 75% of the
interphase cells.
Two independent oligonucleotide-based comparative
genomic hybridization (CGH) analyses were performed
using DNA extracted from the bone marrow specimen
obtained for cytogenetic evaluation at the time of diag-
nosis of B-ALL. These analyses included traditional array
CGH (aCGH) for the detection of copy number alter-
ations and a modification of that technology, transloca-
tion CGH (tCGH), designed to detect a set of balanced
translocations in a single multiplexed assay. Each CGH
assay employed the same microarray platform (Signature
OncoChip™ manufactured by Roche NimbleGen, Madison,
WI) as described in our previous studies [7-9]. For
tCGH, unique DNA primers with an average spacing of
one primer every 2,000–3,500 bp were designed to
linearly amplify genomic regions at recurrent transloca-
tion breakpoints for the specific genes involved.
Primers were assembled into two reaction pools applied
to independent arrays (Pool 1=BCL11A, BCL2, CCND3,
MYC and PAX5 with 36, 14, 33, 4 and 15 primers, respect-
ively; Pool 2=IGH, IGK, and IGL with 19, 50 and 20 primers,
respectively [10] and http://www.signaturegenomics.com/
oncochip_B-cell_ALL.html; OncoChip™ | B-ALL Panel 2).
Linear amplification reactions were performed using the
Failsafe PCR System with Premix Choice using a single buf-
fer (Premix D, Epicentre, Madison, WI, USA), 200 nM for
each primer, and 600 ng genomic DNA. Amplified
DNA and unamplified genomic control DNA were labeled
with independent Cyanine dyes Cy5 and Cy3, respectively
using the NimbleGen Dual-Color DNA Labeling Kit (Roche
NimbleGen), co-precipitated and hybridized to the arrays
and washed as recommended by the manufacturer. Results
were displayed and analyzed with Oncoglyphix® data ana-
lysis and visualization software (Signature Genomics, Perkin
Elmer, Inc., Spokane, WA). aCGH results were consistentFigure 4 FISH confirmation of a double-hit rearrangement. (A) IGH/BC
chromosome. Centromeres of chromosomes 8 and 18 were shown in aqua
fusions were on the same marker chromosome.with a hyperdiploid karyotype. Note that aCGH cannot dis-
cern ploidy. Based on the karyotype findings, normal
microarray results appear to reflect a triploid (3n) genotype.
Consistent aberrations detected by both karyotype
(presented as 3n) and aCGH included whole chromosome
gains for chromosomes 1, 2, 5, 11, 20, 21, 22, X, and Y; par-
tial gains for 6p, 7p, and 13q; as well as losses and partial
losses for chromosomes 8, 9, 12, 15, 17, and 18q (Table 1).
Gene-specific findings included a gain of the distal
long arm of chromosome 8 with a breakpoint near the
distal 5’ end of MYC, and losses of the terminal long
arms of chromosomes 14 and 18 with breakpoints
within the IGH locus and just proximal to BCL2 gene,
respectively (Figure 2). aCGH revealed relatively few
gene-specific alterations that included deletion of NEIL1
(15q24.2), mosaic single copy gain of GPHN (14q22.3)
and amplification of a truncated EP300 allele (22q13.2)
(Table 1). OncoChip™ | B-ALL Panel 2 analysis identified
the IGH/BCL2 fusion as well as a MYC/IGH rearrange-
ment (Figure 3A), which were subsequently confirmed
by FISH and PCR (Figures 2D and 2E, and Figure 3B, re-
spectively). The MYC/IGH/BCL2 complex rearrange-
ment appeared to be on a marker chromosome, which
was further confirmed by using the commercially avail-
able dual fusion FISH probes (Abbott, Abbott Park, IL)
spanning the translocation breakpoints (Figure 4).
Discussion
Follicular lymphoma transforming into acute lympho-
blastic leukemia has been documented in a limited num-
ber of cases [2,3,11,12]. “Double-hit” B-cell malignancies
with both BCL2 and MYC rearrangements have also
been reported in de novo large B-cell lymphoma [13]
and Burkitt’s lymphoma/leukemia with three-way trans-
location t(8;14,18) [14]. Such “Double-hit” B-cell malig-
nancies are characterized by an extremely aggressive
course and a high relapse rate [5,6,13,14]. Given theL2 fusion and (B) MYC/IGH fusion are present on a marker
as indicated. Images of Figures 2E and 3A demonstrated that the
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IGH/BCL2 fusion was likely the first event, with MYC/
IGH fusion arising secondarily and accompanying a
complex karyotype. An early specimen at the time of
diagnosis of FL was not available for this case.
Double-hit translocations in leukemia or lymphoma
rarely occur at a single immunoglobulin locus. Knezevich
et al. reported the detection of a complex der(8)t(8;14;18)
in a few cases with a MYC/IGH/BCL2 rearrangement
resulting from translocation of BCL2 and MYC involving
a single disrupted IGH allele [15]. Molecular cytogenetic
investigation is essential to identify and characterize such
cases. In our case the IGH breakpoints for the BCL2 and
MYC rearrangements were located within the switch re-
gion ([hg18] Chr14:105140803-105142224) and at the
start of the joining region ([hg18] Chr14:105400386-
105400678), respectively, which is consistent with the pre-
vious reports [16]. The MYC breakpoint was located
within intron 1 ([hg18] Chr8:128818114-128818314),
which is also a recurrent site. Most cases of sporadic
Burkitt lymphoma and B-ALL exhibitMYC breakpoints ei-
ther in the first intron, the first exon, or upstream of the
gene [16]. In contrast, the breakpoint for BCL2 was
detected at the 5’ end of the gene ([hg18] Chr18:59135900-
59136028). This is atypical, as BCL2 rearrangements pre-
dominantly involve defined major and minor breakpoint
regions, both of which are 3’ of the gene [16]. 5’- BCL2
breakpoints have been described, but these are rare and
nearly always involve the immunoglobulin light chain, not
seen in this case.
In addition to the MYC/IGH/BCL2 rearrangement,
microarray analysis detected copy number alterations in
this case. Although the majority of the alterations were
large and involved whole chromosomes or whole arm
loss or gain, a few smaller alterations, including deletion
of NEIL1, mosaic single copy gain of GPHN, and ampli-
fication of a truncated EP300 allele were identified.
NEIL1 is a member of the Nei endonuclease VIII-like
gene family which encodes DNA glycosylases. The
NEIL1 encoded enzyme catalyzes the removal of specific
oxidative damage from DNA and interacts with key fac-
tors in cell cycle checkpoints and repair. NEIL1 is among
the genes for which expression levels have been used to
distinguish subtypes of diffuse large B cell lymphoma
[17]. GPHN (for gephyrin, from the Greek word for
“bridge”) is a neuronal receptor assembly protein that
links membrane-associated receptor molecules to cyto-
skeletal microfilaments. Interestingly, GPHN has been
shown as a fusion partner of MLL in leukemia, and the
MLL-GPHN fusion gene can transform hematopoietic
progenitors [18]. GPHN has also been found to be
upregulated by a B-cell- activating factor as part of a
cascade of events that inhibit CD20-mediated and B-cell
receptor-mediated apoptosis in human B cells [19].EP300 encodes the adenovirus E1A-associated cellular
p300 transcriptional co-activator protein. It functions as
a histone acetyltransferase that regulates transcription
via chromatin remodeling and is important in the pro-
cesses of cell proliferation and differentiation. Mutations
in EP300 and the highly related CREBBP are the most
frequent structural abnormalities in follicular lymphoma
and diffuse large B-cell lymphoma [20,21]. In addition,
acquisition of EP300 mutation has recently been shown
in the progression of severe congenital neutropenia to
acute myeloid leukemia [22]. The findings of these add-
itional aberrations may represent events facilitating the
transition of FL to B-ALL. The results presented in this
study identified genomic alterations with potential rele-
vance to transformation and emphasize the value of
employing diverse cytogenetic techniques in the workup
of cases of leukemia and lymphoma.
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